Overview

Oral Nilotinib in Adults With Chronic Myeloid Leukemia (CML) in Blast Crisis Who Are Imatinib Resistant or Intolerant

Status:
No longer available
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This study will evaluate the safety of nilotinib in adult patients with imatinib-resistant or -intolerant CML-blast crisis, CML-accelerated phase or CML-chronic phase when treated with nilotinib. Patients will be provided access to nilotinib until the drug is available on the market.
Details
Lead Sponsor:
Novartis Pharmaceuticals
Treatments:
Imatinib Mesylate